Abstract
Most kinase inhibitors reported so far are designed to bind to a highly conserved ATP binding pocket in a competitive manner. In this case, inhibitors targeting the ATP pocket may crossreact with different kinases, as well as with other proteins that bind ATP, and this may cause undesirable side effects that would limit their clinical usefulness. In addition to the kinase selectivity issues, human ether-a-go-go-related gene (hERG) inhibition could be an obstacle to develop a kinase inhibitor as a safe drug. This paper will review the methods employed in the development of selective kinase inhibitors with several successful examples. These include medicinal chemistry efforts to conquer hERG inhibition problems as sometimes seen in kinase inhibitor programs.
Keywords: Protein Kinase, Inhibitors, ATP, human ether-a-go-go-related gene (hERG), drug, T- Type celcium channels Blockers
Mini-Reviews in Medicinal Chemistry
Title: Strategies for the Design of Selective Protein Kinase Inhibitors
Volume: 8 Issue: 12
Author(s): Masaaki Sawa
Affiliation:
Keywords: Protein Kinase, Inhibitors, ATP, human ether-a-go-go-related gene (hERG), drug, T- Type celcium channels Blockers
Abstract: Most kinase inhibitors reported so far are designed to bind to a highly conserved ATP binding pocket in a competitive manner. In this case, inhibitors targeting the ATP pocket may crossreact with different kinases, as well as with other proteins that bind ATP, and this may cause undesirable side effects that would limit their clinical usefulness. In addition to the kinase selectivity issues, human ether-a-go-go-related gene (hERG) inhibition could be an obstacle to develop a kinase inhibitor as a safe drug. This paper will review the methods employed in the development of selective kinase inhibitors with several successful examples. These include medicinal chemistry efforts to conquer hERG inhibition problems as sometimes seen in kinase inhibitor programs.
Export Options
About this article
Cite this article as:
Sawa Masaaki, Strategies for the Design of Selective Protein Kinase Inhibitors, Mini-Reviews in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/138955708786141043
DOI https://dx.doi.org/10.2174/138955708786141043 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Hepatic Nuclear Factor 1 Alpha (HNF-1α) In Human Physiology and Molecular Medicine
Current Molecular Pharmacology Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Genomic Instability and Cancer
Current Molecular Medicine The Journey From Metabolic Profiling to Biomarkers: The Potential of NMR Spectroscopy Based Metabolomics in Neurodegenerative Disease Research
Current Metabolomics Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Antimicrobial Chitosan based Formulations with Impact on Different Biomedical Applications
Current Pharmaceutical Biotechnology The mRNA-HPV Test Utilization in the Follow Up of HPV Related Cervical Lesions
Current Pharmaceutical Design uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Dual Time F-18 FDG PET/CT Imaging in the Diagnosis of Renal Cell Cancer
Current Medical Imaging Evaluation of Tissue and Serum Expression Levels of Lactate Dehydrogenase Isoenzymes in Patients with Head and Neck Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine N-Oxides as Hypoxia Selective Cytotoxins
Mini-Reviews in Medicinal Chemistry Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Synthesis and Single-Crystal X-Ray Diffraction Studies of an Arylidenethiosemicarbazone and Hydrazonyl-phenylthiazole
Letters in Organic Chemistry Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Abnormal Signal Transduction via Over-expression of Pim-1 Regulated Senescence, Cell Cycle, Apoptosis and Metastatic Invasion: Novel Anticancer Targets and Their Potent Inhibitors from Marine Sources
Current Signal Transduction Therapy